[go: up one dir, main page]

WO2024020577A3 - Anticorps contre le sars-cov-2 - Google Patents

Anticorps contre le sars-cov-2 Download PDF

Info

Publication number
WO2024020577A3
WO2024020577A3 PCT/US2023/070768 US2023070768W WO2024020577A3 WO 2024020577 A3 WO2024020577 A3 WO 2024020577A3 US 2023070768 W US2023070768 W US 2023070768W WO 2024020577 A3 WO2024020577 A3 WO 2024020577A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
antibodies against
sars
against sars
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/070768
Other languages
English (en)
Other versions
WO2024020577A2 (fr
Inventor
Julie OVERBAUGH
Jamie GUENTHOER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of WO2024020577A2 publication Critical patent/WO2024020577A2/fr
Publication of WO2024020577A3 publication Critical patent/WO2024020577A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux ou un fragment de liaison à l'antigène de ceux-ci qui se lient à la protéine de spicule de l'enveloppe virale d'un coronavirus du syndrome respiratoire aigu sévère 2 (SARS-CoV-2). La présente invention concerne également l'utilisation de telles molécules pour détecter et traiter le SARS-CoV-2.
PCT/US2023/070768 2022-07-22 2023-07-21 Anticorps contre le sars-cov-2 Ceased WO2024020577A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263369101P 2022-07-22 2022-07-22
US202263369102P 2022-07-22 2022-07-22
US63/369,101 2022-07-22
US63/369,102 2022-07-22

Publications (2)

Publication Number Publication Date
WO2024020577A2 WO2024020577A2 (fr) 2024-01-25
WO2024020577A3 true WO2024020577A3 (fr) 2024-02-29

Family

ID=89618559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/070768 Ceased WO2024020577A2 (fr) 2022-07-22 2023-07-21 Anticorps contre le sars-cov-2

Country Status (1)

Country Link
WO (1) WO2024020577A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148566A1 (fr) * 2017-02-10 2018-08-16 Adimab, Llc Protéines fixant le bcma, le nkg2d et le cd16
US20210332110A1 (en) * 2020-04-28 2021-10-28 The Rockefeller University Neutralizing Anti-SARS-CoV-2 Antibodies and Methods of Use Thereof
WO2021222128A1 (fr) * 2020-04-27 2021-11-04 Fred Hutchinson Cancer Research Center Anticorps monoclonaux de neutralisation contre la covid-19
WO2022140845A1 (fr) * 2020-12-29 2022-07-07 Val-Chum, Limited Partnership Anticorps monoclonaux de neutralisation contre la covid-19

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148566A1 (fr) * 2017-02-10 2018-08-16 Adimab, Llc Protéines fixant le bcma, le nkg2d et le cd16
WO2021222128A1 (fr) * 2020-04-27 2021-11-04 Fred Hutchinson Cancer Research Center Anticorps monoclonaux de neutralisation contre la covid-19
US20210332110A1 (en) * 2020-04-28 2021-10-28 The Rockefeller University Neutralizing Anti-SARS-CoV-2 Antibodies and Methods of Use Thereof
WO2022140845A1 (fr) * 2020-12-29 2022-07-07 Val-Chum, Limited Partnership Anticorps monoclonaux de neutralisation contre la covid-19

Also Published As

Publication number Publication date
WO2024020577A2 (fr) 2024-01-25

Similar Documents

Publication Publication Date Title
MY197648A (en) Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
MA46731A (fr) Anticorps anti-tmprss2 et fragments de liaison à l'antigène
WO2020169755A3 (fr) Anticorps
CL2010000788A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03).
EP4356924A3 (fr) Anticorps monoclonaux humains contre le coronavirus du syndrome respiratoire aigu severe 2 (sras-cov-2)
CA3179819A1 (fr) Anticorps anti-glycoproteine spike du sars-cov 2 et leurs fragments de liaison a l'antigene
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
MX2022014852A (es) Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2.
MX2023009244A (es) Anticuerpos contra la proteina espicular de coronavirus.
CA3250276A1 (fr) Molécules de liaison à l'antigène ciblant le sars-cov-2
WO2005016132A3 (fr) Diagnostic pour le virus du sras
WO2022032004A3 (fr) Anticorps anti-claudine 18.2 multispécifiques et leurs utilisations
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
WO2022020234A3 (fr) Dosage immunologique pour anticorps neutralisant le sars-cov-2 et matériaux correspondants
WO2024020577A3 (fr) Anticorps contre le sars-cov-2
WO2023159187A3 (fr) Anticorps anti-spicule (s) de sars-cov2 et leurs utilisations
WO2022058618A3 (fr) Anticorps sras-cov-2
WO2021195385A8 (fr) Anticorps monoclonaux humains dirigés contre le coronavirus du syndrome respiratoire aigu sévère 2 (sras-cov-2)
WO2020191181A9 (fr) Anticorps monoclonaux pour la prévention et le traitement d'infections virales de l'herpès simplex
EP4239068A4 (fr) Anticorps capable de se lier spécifiquement à la protéine de nucléocapside du coronavirus-2 responsable du syndrome respiratoire aigu sévère ou à un fragment de celui-ci, et utilisation dudit anticorps ou dudit fragment
WO2023019174A3 (fr) Anticorps contre le sars-cov-2
MX2025001042A (es) Formulaciones de anticuerpos contra tl1a
WO2023016826A3 (fr) Procédé et moyens pour renforcer des anticorps thérapeutiques
WO2024031009A3 (fr) Anticorps anti-cd24 et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23843944

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23843944

Country of ref document: EP

Kind code of ref document: A2